PRESERVE is a multi-center, prospective, open-label, non-randomized investigation of commercially available IVC filters from 6 manufacturers placed in subjects for the prevention of pulmonary embolism (PE). This study will enroll approximately 1,800 IVC filter subjects at up to 60 sites in the US. All treated subjects will be evaluated at procedure, 3-months, 6-months (phone), 12-months, 18-months (phone), and 24-months post-procedure. The primary objective of this investigational device exemption (IDE) clinical investigation is to evaluate the safety and effectiveness of the commercially available IVC filters (retrievable and permanent) in subjects with clinical need for mechanical prophylaxis of PE with an IVC filter.
Pulmonary Embolisminferior vena cava filters
You can join if…
Open to people ages 18 years and up
Male or Female, age 18 years or older;
Requires IVC filter for prevention of pulmonary embolism (PE);
Provide written informed consent and written HIPAA authorization prior to initiation of study procedures;
Willing to comply with the specified follow-up
You CAN'T join if...
Subject is unable to participate in study evaluations pre- and post-treatment
Known sensitivity to contrast or serious contrast reaction such as anaphylaxis for which premedication is known to be unsuccessful in alleviating symptoms
University of California San Franciscoaccepting new patients San Francisco, California, 94118, United States
Palo Alto VAaccepting new patients Palo Alto, California, 94304, United States
Ronald Regan UCLA Medical Centeraccepting new patients Los Angles, California, 90024, United States
Harbor-UCLA Medical Centeraccepting new patients Torrance, California, 90502, United States